Worth reading
65In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
982000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Report on the exercise status of the 10th Series of Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clause)
Who receives how much
982,000 new shares (number of shares delivered in May 2026)
EVO FUND (issued on 13 February 2026)
The lower thin line represents the existing number of shares to which these shares will be added.
Existing Shares and Increase
+8.80%Rate of increase
11,118,500 shares12,100,500Shares
982,000 shares delivered during the subject month / 11,118,500 issued shares as of the end of the month preceding the subject month (approximately 8.8%)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
The exercise prices during the subject month were ¥109, ¥111, ¥113 and ¥117. Details of the adjustment clause and the adjustment floor are not disclosed.
Number of Stock Acquisition Rights
Total issued: 82,700; exercised during the subject month: 9,820; unexercised at the end of the subject month: 59,980
Procedures under the Corporate Code of Conduct
Report on compliance with the exercise restrictions under Article 434 of the Listing Regulations. The exercise ratio subject to the exercise restrictions was 10.0%.
Most recent equity financing
Issued on 13 February 2026: 10th Series Stock Acquisition Rights (with Exercise Price Adjustment Clause). Amount not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Report on the exercise status of the 10th Series of Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clause) |
| Number of shares to be issued or disposed of | 982,000 new shares (number of shares delivered in May 2026) |
| Intended allottee | EVO FUND (issued on 13 February 2026) |
| Dilution Rate | 982,000 shares delivered during the subject month / 11,118,500 issued shares as of the end of the month preceding the subject month (approximately 8.8%) |
| Total number of issued shares | 11,118,500 shares (as of the end of the month preceding the subject month) → 12,100,500 shares (the number obtained by adding the shares delivered during the subject month to the number of shares at the end of the preceding month)（Approximately 8.8%） |
| Exercise price | The exercise prices during the subject month were ¥109, ¥111, ¥113 and ¥117. Details of the adjustment clause and the adjustment floor are not disclosed. |
| Number of Stock Acquisition Rights | Total issued: 82,700; exercised during the subject month: 9,820; unexercised at the end of the subject month: 59,980 |
| Procedures under the Corporate Code of Conduct | Report on compliance with the exercise restrictions under Article 434 of the Listing Regulations. The exercise ratio subject to the exercise restrictions was 10.0%. |
| Most recent equity financing | Issued on 13 February 2026: 10th Series Stock Acquisition Rights (with Exercise Price Adjustment Clause). Amount not disclosed |
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status for May 2026. No other reason for the exercises is stated.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.